EZH2 and prostate adenocarcinoma: Additionally, we observed that EZH2 inhibition suppressed inflammatory signaling, consistent with prior work suggesting that inflammatory reprogramming is required for lineage transition from prostate adenocarcinoma to NEPC (5).